Mantle cell lymphoma (MCL) is a B cell malignancy with unique biological, pathological and clinical features comprising 3–10% of all non-Hodgkin lymphomas (NHLs) (Swerd-low et al, 1983). It was recognised as a speciﬁc entity in the revised European-American classiﬁcation of lymphoid neo-plasms (REAL) classiﬁcation (Harris et al, 1994) and is characterized by the chromosomal translocation t(11;14)(q13-3;q32-33), resulting in over-expression of the cell cycle protein cyclin D1 (Akiyama et al, 1994; Campo et al, 1999).
Declaration of Interests
The BSH paid the expenses incurred during the writing of this guidance. None of the authors had conflicts of interest to declare. All authors have made a declaration of interests to the BSH and Task Force Chairs which may be viewed on request.